OncoMatch/Clinical Trials/NCT05672147
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Is NCT05672147 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Anti-CD33 CAR T-cells for acute myeloid leukemia.
Treatment: Anti-CD33 CAR T-cells — This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's or donor's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CD33 positive (positive)
Prior therapy
Cannot have received: allogeneic transplant
Exception: allowed if > 6 months prior to study enrollment
Prior allogeneic transplant if < 6 months prior to enrollment
Lab requirements
Kidney function
Estimated creatinine clearance of >= 60 mL/min per Cockcroft-Gault formula, not on hemodialysis
Liver function
Total serum bilirubin <= 2.0 mg/dL (<= 3.0 mg/dL if Gilbert syndrome); AST <= 3 x ULN; ALT <= 3 x ULN
Cardiac function
Left ventricular ejection fraction >= 50% within 8 weeks before enrollment
Total serum bilirubin <= 2.0 mg/dL; Participants with Gilbert syndrome may be included if their total bilirubin is <= 3.0; AST <= 3 x ULN; ALT <= 3 x ULN; Estimated creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula, and the participant is not on hemodialysis; Left ventricular ejection fraction >= 50% within 8 weeks before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05672147 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic transplant disqualifies patients from enrollment.
Does this trial require CD33?
Yes, CD33 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages